Navigation Links
FDLI, PEN co-sponsor major conference on nanotechnology
Date:12/10/2007

Nanotechnology was incorporated into more than $50 billion in manufactured goods last year, according to Lux Research. By 2014, the market will grow to $2.6 trillion. By 2011, over $15 billion in nano-enabled drugs and therapeutics will be soldup from more than $3 billion in 2006. And industry experts project that nanotechnology will be incorporated into $20 billion worth of consumer food products by 2010.

Yet, despite this rapid commercialization, no nano-specific regulation exists anywhere in the world. Most regulatory agencies remain in an information-gathering modelacking the legal and scientific tools, information and resources they need to adequately oversee exponential nanotechnology market growth.

Now, for the first time, top officials at the agencies responsible for the regulation of nanotechnology productsincluding the Food and Drug Administration, Environmental Protection Agency, Occupational Safety and Health Administration and Department of Agriculturewill meet at a Food and Drug Law Institute conference to discuss their plans for managing and monitoring these products.

At FDLIs 1st Annual Conference on Nanotechnology Law, Regulation and Policy, February 28-29, 2008, at the LEnfant Plaza Hotel, in Washington, DC, food and drug industry representatives also will find out whats happening internationally on nanotech regulation, how venture capitalists look at the future of nanotechnology and what the leading corporations, scientific laboratories and academic centers are focusing on in this dynamic field.

This groundbreaking conference, co-sponsored by the Woodrow Wilson International Center for Scholars Project on Emerging Nanotechnologies, in partnership with Arizona State University and the Burdock Group, will address the crucial issues surrounding nanotechnology law, regulation and policy, including:

  • What first and second generation nanotechnology products already are on the market, and what is to come?
  • Is Congress ready to act on nanotechnology if federal regulators do not?
  • Do Europe and Asia approach nanotechnology safety and oversight differently than the United States?
  • How do consumers see nanoproducts?
  • When it comes to nanotechnology, should size make a regulatory difference?

Michael Taylor, Research Professor of Health Policy, School of Public Health and Health Services, The George Washington University, and author of the most comprehensive report published on nanotechnology regulation at FDA, Regulating the Products of Nanotechnology, Does FDA Have the Tools It Needs?, will present the keynote address. Also, Sen. Ron Wyden (D-Ore.), co-chair of the Congressional Nanotechnology Caucus, and invited luncheon speaker, will discuss future congressional actions in this area.

Top-level FDA officials, including Associate Commissioner for Science Norris Alderson; Deputy Commissioner for Policy Randall W. Lutter; Deputy Associate General Counsel Jeffrey Senger; and Director of Food Additive Safety Laura Tarantino, will appear on a special panel on FDA regulation of nanotechnology.

Other featured speakers and moderators include:

Jay M. Ansell, Personal Care Products Council;
Susan D. Brienza, Of Counsel, Patton Boggs LLP;
George Burdock, President, Burdock Group;
Robert W. Carpick; University of Pennsylvania Director, The Nanotechnology Institute;
Ricardo Carvajal; Counsel, Reed Smith LLP;
Jim Czaban, Partner, WilmerHale;
Lee Farrow, Senior Vice President, ACE Medical Risk;
Piotr Grodzinski, Director, NCI Alliance for Nanotechnology in Cancer, NIH;
Ralph Hall, Professor, University of Minnesota Law School;
Robert A. Hoerr, President & CEO, Nanocopoeia, Inc.;
Michael Holman. Senior Analyst, Lux Research;
Karen Hunter, Program Specialist, U.S. Department of Agriculture, Cooperative State Research, Education and Extension Service;
Rachel G. Lattimore, Partner, Arent Fox LLP;
Scott Livingston, Managing Director, Axiom Capital Management/The Livingston Group;
Jane Macoubrie, President, Embry Research;
Ellen Maldenado, Attorney-at-Law;
Gary Marchant, Lincoln Professor of Emerging Technologies, Law & Ethics
Sandra Day OConnor College of Law;
Philippe Martin, Principal Administrator, Nanotechnologies Policy Development and Coordination, Consumer Protection Directorate (DG-SANCO), European Commission;
Terry L. Medley, Global Director, Corporate Regulatory Affairs, DuPont Environment and Sustainable Growth Center;
Julia A. Moore, Deputy Director, Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars;
Sean Murdock, Executive Director, NanoBusiness Alliance;
Fern P. OBrian, Partner, Arnold & Porter LLP;
Leon Radomsky, Chair, Nanotechnology Industry Team, Foley & Lardner LLP;
David W. Rejeski, Director, Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars;
Stephanie Scharf, Partner, Schoeman Updike Kauffman & Scharf;
Dietram Scheufele, Professor of Life Sciences Communication, University of Wisconsin;
Loretta Schuman, Occupational Safety and Health Administration;
Laura Sciarrino, Vice President, Legal, CV Therapeutics, Inc.; and
Jim Willis, U.S. Environmental Protection Agency.


'/>"/>

Contact: Michael Levin-Epstein
mdl@fdli.org
202-222-0897
Project on Emerging Nanotechnologies
Source:Eurekalert

Related biology news :

1. deCODE discovers cause of major subtype of glaucoma
2. Bleeding, not inflammation, is major cause of early lung infection death
3. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
4. Leading experts cite poor health and nutrition as major barrier to education in developing world
5. Majority of Americans want local action on global warming, says poll
6. How schizophrenia develops: Major clues discovered
7. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
8. NIH selects LIAI for major study on allergy molecular causes and possible treatments
9. Local sources major cause of US near-ground aerosol pollution
10. Tree of life for flowering plants reveals relationships among major groups
11. Humans not the major target of Shiga toxin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... ... , ... The award-winning American Farmer television series will feature 3 Bar Biologics ... at 8:30aET on RFD-TV. , With global population estimates nearing ten billion people ... to feed a growing nation. At the same time, many of our valuable resources ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
Breaking Biology Technology: